Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...

Ariceum Therapeutics GmbH’s radiopharmaceutical 225Ac-SSO110 ([225Ac]satoreotide tetraxetran) has been awarded orphan drug designation by the FDA for the treatment of small-cell lung cancer (SCLC).

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at where Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands against other ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Crinetics Pharmaceuticals (NasdaqGS:CRNX) with ...

ITM-11, the drug that ITM says succeeded in the Phase 3 neuroendocrine cancer study, contains the isotope lutetium-177, which is packaged together with a compound that targets a protein known as the ...

Fintel reports that on January 22, 2025, Jefferies upgraded their outlook for Crinetics Pharmaceuticals (NasdaqGS:CRNX) from Hold to Buy. Analyst Price Forecast Suggests 94.74% Upside As of December ...

Study of 2.4 million participants reveals potential advantages for cardiometabolic and psychiatric conditions alongside increased risks of gastrointestinal and musculoskeletal issues Study ...